返回
Innovent Biologics, Inc.（1801.HK）價格
1801.HK 股價走勢圖
INNOVENT BIO (1801.HK)
Innovent Biologics, Inc.
HK$84.7
-3.96%
$-3.5
休市： Jan 19, 16:00:00 HKT
關鍵數據
前收市價
$89.5
開盤價
$88.2
當日範圍
$83.6 - $89.35
52週區間
$30.75 - $109.1
交易量
8.5M
平均成交量
14.1M
每股盈餘 (TTM)
0.74
股息收益率
--
市值
$145.7B
什麼是 INNOVENT BIO？
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 6,190 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly conducts its businesses within domestic and overseas markets.